Lee K W, Mossine V, Ortwerth B J
Mason Institute of Ophthalmology, University of Missouri, Columbia 65212, USA.
Exp Eye Res. 1998 Jul;67(1):95-104. doi: 10.1006/exer.1998.0500.
Nonenzymatic glycation by glucose and/or ascorbate leads to the formation of advanced glycation end products (AGEs), which are thought to be a critical element in lens protein aging and cataract formation. The relative participation of these two glycating agents was evaluated in vitro. The incubation of 100 mM [U-14C]-D-glucose and 10 mM [U-14C]-L-ascorbate with lens proteins resulted in an increasing incorporation over 3 weeks, reaching a maximum of 100 nMol mg-1 protein and 160 nMol mg-1 protein with ascorbate. Glycation was proportional to carbohydrate concentration with both reagents, however ascorbate was 18-fold more reactive with lens proteins than glucose. Protein crosslinking was not obvious with 250 mM glucose as measured by SDS-PAGE, however, ascorbate caused extensive crosslinking even at 3.0 mM. The sugar-dependent incorporation of N alpha-formyl-[U-14C]-L-lysine ([U-14C]Nfl) into proteins, gave values of 1.5 nMol mg-1 protein after 3 weeks with 100 mM glucose compared to 11 nMol mg-1 protein with 10 mM ascorbate. On a molar basis, ascorbate was 70-fold more active than glucose and 100-fold more active than fructose in the crosslinking assay. N alpha-formyl-N epsilon-fructosyllysine (1.0 mM) dissociated to cause the incorporation of 1.2 nMol of [U-14C]NfL, but 1.0 mM 3-deoxyglucosone, the putative active dissociation product of fructosyl-lysine, produced only 1.5 nMol mg-1 protein of crosslinks. The chelator, DTPA, had little or no effect on crosslinking in our assay except at the highest carbohydrate level. These data argue that glucose crosslinking can be shown in vitro with lens proteins, however, it does not proceed significantly via 3-deoxyglucosone, and does not require transition metal ion-mediated oxidation to occur. Quantitatively, however, it is almost two orders of magnitude less than the crosslinking by ascorbate oxidation products in vitro.
葡萄糖和/或抗坏血酸的非酶糖基化会导致晚期糖基化终产物(AGEs)的形成,这些产物被认为是晶状体蛋白老化和白内障形成的关键因素。在体外评估了这两种糖基化剂的相对参与情况。将100 mM [U-14C]-D-葡萄糖和10 mM [U-14C]-L-抗坏血酸与晶状体蛋白一起孵育,在3周内掺入量不断增加,抗坏血酸处理时最高达到100 nMol mg-1蛋白和160 nMol mg-1蛋白。两种试剂的糖基化都与碳水化合物浓度成正比,然而抗坏血酸与晶状体蛋白的反应活性比葡萄糖高18倍。用SDS-PAGE检测,250 mM葡萄糖处理时蛋白交联不明显,然而,即使在3.0 mM时抗坏血酸也会导致广泛交联。3周后,100 mM葡萄糖处理时Nα-甲酰基-[U-14C]-L-赖氨酸([U-14C]Nfl)掺入蛋白的值为1.5 nMol mg-1蛋白,而10 mM抗坏血酸处理时为11 nMol mg-1蛋白。在交联试验中,按摩尔计算,抗坏血酸的活性比葡萄糖高70倍,比果糖高100倍。1.0 mM Nα-甲酰基-Nε-果糖基赖氨酸解离导致掺入1.2 nMol的[U-14C]NfL,但1.0 mM 3-脱氧葡萄糖酮(果糖基赖氨酸的假定活性解离产物)仅产生1.5 nMol mg-1蛋白的交联。螯合剂二乙三胺五乙酸(DTPA)在我们的试验中对交联几乎没有影响,除非在最高碳水化合物水平。这些数据表明,葡萄糖交联在体外可与晶状体蛋白发生,但它不是通过3-脱氧葡萄糖酮显著进行的,也不需要过渡金属离子介导的氧化来发生。然而,从数量上看,它比体外抗坏血酸氧化产物的交联少近两个数量级。